NASDAQ:LVGOLivongo Health Stock Price, Forecast & News

Livongo Health's stock was trading at $25.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LVGO shares have increased by 327.5% and is now trading at $107.56. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Livongo Health in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Livongo Health.

Livongo Health is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Livongo Health.

Livongo Health will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Livongo Health (NASDAQ:LVGO) announced its quarterly earnings results on Wednesday, May, 6th. The company reported $0.03 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.07. The business had revenue of $68.80 million for the quarter, compared to the consensus estimate of $66.11 million. Livongo Health had a negative net margin of 22.05% and a negative return on equity of 11.81%. The company's revenue was up 114.3% compared to the same quarter last year. View Livongo Health's earnings history.

Livongo Health issued an update on its second quarter 2020 Pre-Market earnings guidance on Tuesday, July, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $86-87 million, compared to the consensus revenue estimate of $74.97 million.

16 brokers have issued 1-year price objectives for Livongo Health's stock. Their forecasts range from $30.00 to $120.00. On average, they anticipate Livongo Health's share price to reach $74.50 in the next year. This suggests that the stock has a possible downside of 30.7%. View analysts' price targets for Livongo Health.

Media coverage about LVGO stock has been trending negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Livongo Health earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Livongo Health.

Livongo Health saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 6,470,000 shares, an increase of 54.8% from the June 15th total of 4,180,000 shares. Based on an average trading volume of 3,160,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 15.9% of the shares of the company are sold short. View Livongo Health's Current Options Chain.

Some companies that are related to Livongo Health include Snap (SNAP), IHS Markit (INFO), Twitter (TWTR), Trade Desk (TTD), Yandex (YNDX), Pinterest (PINS), Wix.Com (WIX), GDS (GDS), FactSet Research Systems (FDS), Line (LN), Weibo (WB), 58.com (WUBA), Legend Biotech (DADA), HUYA (HUYA) and Switch (SWCH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Livongo Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Advanced Micro Devices (AMD), Paypal (PYPL), Twilio (TWLO), Marvell Technology Group (MRVL), Zoom Video Communications (ZM), Alteryx (AYX) and salesforce.com (CRM).

(LVGO) raised $230 million in an initial public offering on Thursday, July 25th 2019. The company issued 10,700,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and Piper Jaffray, SVB Leerink, Canaccord Genuity, KeyBanc Capital Markets and Needham & Company were co-managers.

Livongo Health trades on the NASDAQ under the ticker symbol "LVGO."

Livongo Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Spence Asset Management (0.23%) and Mount Yale Investment Advisors LLC (0.01%). Company insiders that own Livongo Health stock include Ab (Publ) Kinnevik, Christopher Bischoff, Gc Venture Lh Manager, Llc, Glen Tullman, Hemant Taneja, James Pursley, Jennifer Schneider and Lee Shapiro. View institutional ownership trends for Livongo Health.

LVGO stock was acquired by a variety of institutional investors in the last quarter, including Spence Asset Management, and Mount Yale Investment Advisors LLC. Company insiders that have bought Livongo Health stock in the last two years include Ab (Publ) Kinnevik, Christopher Bischoff, Gc Venture Lh Manager, Llc, and Hemant Taneja. View insider buying and selling activity for Livongo Health.

Shares of LVGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LVGO stock can currently be purchased for approximately $107.56.

Livongo Health has a market capitalization of $10.52 billion and generates $170.20 million in revenue each year. The company earns $-55,270,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Livongo Health employs 471 workers across the globe.

The official website for Livongo Health is www.livongo.com.

Livongo Health's mailing address is 150 WEST EVELYN AVENUE SUITE 150, MOUNTAIN VIEW CA, 94041. The company can be reached via phone at 866-435-5643 or via email at [email protected]